OVERVIEW

Over the last six years, CCI designed and led several programs focused on expanding access to treatment for people with opioid use disorder (OUD). Combined, these programs supported more than 100 primary care health centers in California with designing new or expanding existing medications for addiction treatment (MAT) programs. MAT includes FDA-approved medications for OUD: methadone, buprenorphine, and naltrexone.

The programs increased the number of active MAT prescribers by 191 providers — equivalent to more than two active prescribers per participating clinic. In addition, there was a combined increase of more than 2,199 patients receiving MAT. Many participants doubled or tripled the number of patients accessing MAT for OUD. Central to these successes was the creation of learning communities which offered a structured forum to develop new capabilities, share best practices, and discuss lessons learned.

Now we’re building on that success with a fourth wave of programming to support California community health centers’ identification and treatment of substance use disorders. Applications officially open on November 9. There are two program tracks: